2,000 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by Quarry LP

Quarry LP acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,000 shares of the company’s stock, valued at approximately $95,000.

Other institutional investors have also modified their holdings of the company. Values First Advisors Inc. purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the last quarter. Comerica Bank lifted its position in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter worth approximately $139,000. Finally, Quest Partners LLC lifted its position in shares of Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after buying an additional 4,865 shares during the last quarter.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 15.82% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KYMR. Oppenheimer boosted their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Finally, UBS Group cut their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.50.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $46.67 on Friday. The company’s fifty day moving average is $46.40 and its two-hundred day moving average is $42.54. Kymera Therapeutics, Inc. has a one year low of $21.20 and a one year high of $53.27. The firm has a market capitalization of $3.02 billion, a P/E ratio of -19.94 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter last year, the firm earned ($0.90) earnings per share. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.